Free Trial
NYSE:BIO.B

Bio-Rad Laboratories (BIO.B) Stock Price, News & Analysis

Bio-Rad Laboratories logo
$247.05 0.00 (0.00%)
As of 09/2/2025

About Bio-Rad Laboratories Stock (NYSE:BIO.B)

Key Stats

Today's Range
$247.05
$247.05
50-Day Range
$247.05
$289.13
52-Week Range
$225.29
$359.22
Volume
92 shs
Average Volume
29 shs
Market Capitalization
$6.72 billion
P/E Ratio
21.06
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive BIO.B Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIO.B Stock News Headlines

An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
Bio-Rad Labs B (BIOb) Earnings Dates & Reports
Bio-Rad price target lowered to $409 from $430 at RBC Capital
See More Headlines

BIO.B Stock Analysis - Frequently Asked Questions

Bio-Rad Laboratories' stock was trading at $325.60 on January 1st, 2025. Since then, BIO.B stock has decreased by 24.1% and is now trading at $247.05.

Bio-Rad Laboratories, Inc. (NYSE:BIO.B) announced its earnings results on Thursday, July, 31st. The company reported $2.61 earnings per share (EPS) for the quarter. Bio-Rad Laboratories had a net margin of 12.50% and a trailing twelve-month return on equity of 4.01%.

Bio-Rad Laboratories subsidiaries include Celsee, Raindance Technologies Limited, GnuBIO Inc., Bio-Rad AbD Serotec GmbH, QuantaLife, DiaMed Holding AG, Blackhawk Biosystems, and others.

Shares of BIO.B stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
7/31/2025
Today
9/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Measuring And Control Equipment
Current Symbol
NYSE:BIO.B
CIK
12208
Employees
8,200
Year Founded
1952

Profitability

EPS (Trailing Twelve Months)
$11.73
Trailing P/E Ratio
21.06
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$1.84 billion
Net Margins
12.50%
Pretax Margin
17.62%
Return on Equity
4.01%
Return on Assets
2.82%

Debt

Debt-to-Equity Ratio
0.17
Current Ratio
5.12
Quick Ratio
3.67

Sales & Book Value

Annual Sales
$2.57 billion
Price / Sales
2.62
Cash Flow
$10.39 per share
Price / Cash Flow
23.77
Book Value
$261.96 per share
Price / Book
0.94

Miscellaneous

Outstanding Shares
27,210,000
Free Float
19,490,000
Market Cap
$6.72 billion
Optionable
Not Optionable
Beta
0.78

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NYSE:BIO.B) was last updated on 9/4/2025 by MarketBeat.com Staff
From Our Partners